The majority of patients with esophageal cancer present with advanced disease and chemotherapy is the mainstay of palliation. However, efficacy is limited by the development of chemotherapy resistance and treatment options beyond first- and second-line treatment are scarce. Immunotherapy is a novel treatment option that has shown encouraging efficacy in several types of cancer, also in esophageal cancer. In esophageal squamous cell cancer (ESCC), early phase evaluation of immune checkpoint inhibitors has yielded promising results, however, results from phase 3 trials are currently still lacking. Besides checkpoint inhibitors, other immunogenic approaches e.g. peptide vaccines, adoptive T-cell therapy and oncolytic viruses are under development. This review describes the biological rational for immunotherapy and provides first accumulating data on its use in advanced esophageal cancer, with a focus on ESCC.

Journal Section:
Review Article
Keywords:
Chemotherapy, Esophageal Cancer, Immunotherapy
1.
Torre LA, Bray F, Siegel RL, et al.: Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2.
Lordick F, Mariette C, Haustermans K, et al.: Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27: v50-v57.
3.
Network CGAR: Integrated genomic characterization of oesophageal carcinoma. Nature 2017;541:169-175.
4.
Lawrence MS, Stojanov P, Polak P, et al.: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-218.
5.
Network CGAR: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-209.
6.
Alsina M, Moehler M, Hierro C, et al.: Immunotherapy for gastric cancer: a focus on immune checkpoints. Target Oncol 2016;11:469-477.
7.
Whiteside T: The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27:5904-5912.
8.
Vogelstein B, Papadopoulos N, Velculescu VE, et al.: Cancer genome landscapes. Science 2013;339:1546-1558.
9.
Yarchoan M, Hopkins A, Jaffee EM: Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 2017;377:2500-2501.
10.
Kojima T, Doi T: Immunotherapy for esophageal squamous cell carcinoma. Curr Oncol Rep 2017;19:33.
11.
Lim S, Hong M, Ahn S, et al.: Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. Eur J Cancer 2016;52:1-9.
12.
Ostrand-Rosenberg S, Horn LA, Haile ST: The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol 2014;193:3835-3841.
13.
Cho Y, Miyamoto M, Kato K, et al.: CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 2003;63:1555-1559.
14.
Doi T, Piha-Paul SA, Jalal SI, et al.: Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol 2018;36:61-67.
15.
Kudo T, Hamamoto Y, Kato K, et al.: Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol 2017;18:631-639.
16.
Ribas A, Robert C, Hodi FS, et al.: Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol 2015; 33(suppl15):3001-3001.
17.
Muro K, Chung HC, Shankaran V, et al.: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016;17:717-726.
18.
Mole R: Whole body irradiation - radiobiology or medicine? Br J Radiol 1953;26:234-241.
19.
Salama AK, Postow MA, Salama JK: Irradiation and immunotherapy: from concept to the clinic. Cancer 2016;122:1659-1671.
20.
Tang C, Wang X, Soh H, et al.: Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res 2014;2:831-838.
21.
Kroemer G, Galluzzi L, Kepp O, Zitvogel L: Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013;31:51-72.
22.
Twyman-Saint Victor C, Rech AJ, Maity A, et al.: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015;520:373-377.
23.
Kelly RJ, Lockhart AC, Jonker DJ, et al.: CheckMate 577: a randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer. J Clin Oncol 2017;35(suppl4): TPS212-TPS212.
24.
Kumai T, Kobayashi H, Harabuchi Y, Celis E: Peptide vaccines in cancer - old concept revisited. Curr Opin Immunol 2017;45:1-7.
25.
Kimura T, Egawa S, Uemura H: Personalized peptide vaccines and their relation to other therapies in urological cancer. Nat Rev Urol 2017;14:501-510.
26.
Kageyama S, Wada H, Muro K, et al.: Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med 2013;11:246.
27.
Iinuma H, Fukushima R, Inaba T, et al.: Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med 2014;12:84.
28.
Gill S, Maus MV, Porter DL: Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev 2016;30:157-167.
29.
Robbins PF, Kassim SH, Tran TL, et al.: A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 2015;21:1019-1027.
30.
Kageyama S, Ikeda H, Miyahara Y, et al.: Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res 2015;21:2268-2277.
31.
Moehler M, Goepfert K, Heinrich B, et al.: Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus H-1. Front Oncol 2014;4:92.
32.
Ungerechts G, Engeland CE, Buchholz CJ, et al.: Virotherapy research in Germany: from engineering to translation. Hum Gene Ther 2017;28:800-819.
33.
Larson C, Oronsky B, Scicinski J, et al.: Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget 2015;6:19976-19989.
34.
Rojas JJ, Sampath P, Hou W, Thorne SH: Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy. Clin Cancer Res 2015;21:5543-5551.
35.
Heinrich B, Klein J, Delic M, et al.: Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. Onco Targets Ther 2017;10:2389-2401.
36.
Kaufman HL, Andtbacka RHI, Collichio FA, et al.: Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol 2014;32(suppl5):9008a-9008a.
37.
Yajima S, Ino Y, Fukuhara H, et al.: Abstract 412. The efficacy and bio-distribution of oncolytic HSV-1 (G47Δ) in mouse orthotopic esophageal cancer models. Mol Ther 2016;24:S163.
38.
Stiles BM, Bhargava A, Adusumilli PS, et al.: The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. Surgery 2003;134:357-364.
39.
Tanabe S, Tazawa H, Kagawa S, et al.: Abstract CT123. Phase I/II trial of endoscopic intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, with radiation in elderly esophageal cancer patients. Cancer Res 2015;75(suppl15):CT123.
40.
Cristescu R, Lee J, Nebozhyn M, et al.: Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015;21:449-456.
41.
Le DT, Uram JN, Wang H, et al.: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-2520.
42.
Secrier M, Li X, De Silva N, et al.: Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet 2016;48:1131-1141.
43.
Maron SBLJJ, Hovey R, Bao R, et al.: Molecular characterization of T-cell-inflamed gastroesophageal carcinoma in TCGA. Abstract, in the 32nd Annual Meeting & Pre-Conference Programs, The Society for Immunotherapy of Cancer (SITC), November 2017.
44.
Thompson ED, Zahurak M, Murphy A, et al.: Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 2017;66:794-801.
45.
Derks S, Liao X, Chiaravalli AM, et al.: Abundant PD-L1 expression in Epstein-Barr virus-infected gastric cancers. Oncotarget 2016;7:32925-32932.
46.
Parkes EE, Blayney JK, McCarron E, et al.: PD-L1 expression and response to neo-adjuvant chemotherapy in esophageal adenocarcinoma. J Clin Oncol 2017;35(suppl15):4023-4023.
47.
Kelly RJ, Zaidi AH, Smith MA, et al.: Magnitude and duration of immune checkpoint up-regulation and changes in the immune microenvironment post chemo-radiation (CRT) in esophageal cancer. J Clin Oncol 2017;35(suppl15):4060.
48.
Fuchs CS, Ohtsu A, Tabernero J, et al.: Preliminary safety data from KEYNOTE-059: pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer. J Clin Oncol 2016;34(suppl15):4037.
49.
Janjigian YY, Bendell JC, Calvo E, et al.: CheckMate-032: phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). J Clin Oncol 2016;34(suppl15):4010.
50.
Boku N, Kang Y, Satoh T, et al.: Abstract 617O. A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: updated results and subset analysis by PD-L1 expression (ATTRACTION-02). Ann Oncol 2017;28(suppl5):mdx369.001.
51.
Chung HC AH, Wyrwicz L, et al.: Avelumab (MSB0010718C), anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer: a phase Ib trial. Eur J Cancer 2015;51(suppl): S457, Abstr 2364.
52.
Le DT, Uram JN, Wang H, et al.: PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. J Clin Oncol 2016;34(suppl 4):195.
© 2018 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.